Annual report pursuant to Section 13 and 15(d)

Debt - Textual (Details)

v3.6.0.2
Debt - Textual (Details)
1 Months Ended 12 Months Ended
Nov. 05, 2015
USD ($)
Apr. 01, 2015
d
$ / shares
Aug. 30, 2013
USD ($)
conversion_right
shares
Jun. 30, 2014
USD ($)
shares
Jan. 31, 2013
$ / shares
Rate
Dec. 31, 2016
USD ($)
institution
$ / shares
Rate
shares
Dec. 31, 2015
USD ($)
institution
$ / shares
Rate
Dec. 31, 2014
USD ($)
$ / shares
Rate
Aug. 31, 2015
USD ($)
Jan. 30, 2013
USD ($)
Aug. 31, 2012
USD ($)
Debt Instrument [Line Items]                      
Interest paid           $ 2,890,000 $ 4,572,000 $ 6,276,000      
Gains (losses) on extinguishment of debt           284,000 (943,000) (2,668,000)      
Gain (loss) on embedded derivative           (7,000,000) 36,600,000        
Credit line capacity           190,713,000          
Goodwill           $ 704,603,000 $ 743,348,000 224,292,000      
Number of financial institutions | institution           10 10        
Bio-Reference Laboratories, Inc.                      
Debt Instrument [Line Items]                      
Net assets           $ 1,000,000,000          
Goodwill           401,821,000     $ 401,821,000    
Intangible assets           $ 488,700,000     $ 545,250,000    
OPKO Health Europe                      
Debt Instrument [Line Items]                      
Goodwill                     $ 8,062,000
Intangible assets                     $ 8,378,000
Weighted average interest rate           3.20% 4.30%        
Minimum | OPKO Health Europe                      
Debt Instrument [Line Items]                      
Variable interest rates           1.80%          
Maximum | OPKO Health Europe                      
Debt Instrument [Line Items]                      
Variable interest rates           6.30%          
Notes                      
Debt Instrument [Line Items]                      
Principal balance           $ 43,701,000 $ 48,986,000 $ 129,816,000      
Notes | Notes Due February 1, 2033                      
Debt Instrument [Line Items]                      
Debt face amount                   $ 175,000,000.0  
Interest rate of notes payable           3.00% 3.00% 3.00%   3.00%  
Equivalent redemption price         100.00%            
Conversion rate | Rate         14.14827% 14.14827% 14.14827% 14.14827%      
Conversion price (in dollars per share) | $ / shares   $ 7.07     $ 7.07 $ 7.07 $ 7.07 $ 7.07      
Convertible debt, threshold percentage of stock price trigger   130.00%     130.00% 130.00%          
Number of consecutive trading days applicable conversion price   30 days                  
Conversion rights triggered | conversion_right     1                
Convertible notes, conversion     $ 16,900,000     $ 55,400,000          
Convertible debt, stock issued from conversion (in shares) | shares     2,396,145     8,118,062          
Converted amount       $ 70,400,000              
Interest paid       $ 800,000              
Common stock trigger price (in usd per share) | $ / shares   $ 9.19       $ 9.19          
Threshold trading days | d   20                  
Principal balance           $ 31,900,000 $ 32,200,000 $ 87,600,000      
Estimated credit spread | Rate           7.65% 11.42% 10.81%      
Notes | Notes Due February 1, 2033 | Minimum                      
Debt Instrument [Line Items]                      
Number of trading days         20 days 20 days          
Notes | Notes Due February 1, 2033 | Maximum                      
Debt Instrument [Line Items]                      
Number of consecutive trading days applicable conversion price         30 days 30 days          
Notes | Notes Due February 1, 2033 | On or after February 1, 2017 and before February 1, 2019                      
Debt Instrument [Line Items]                      
Equivalent redemption price         100.00%            
Line of Credit                      
Debt Instrument [Line Items]                      
Weighted average interest rate           4.70% 4.30%        
Common stock investments, available for sale | Notes | Notes Due February 1, 2033                      
Debt Instrument [Line Items]                      
Convertible debt, stock issued from conversion (in shares) | shares       10,974,431              
Revolving Credit Facility | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Credit line capacity $ 175,000,000.0                    
Higher borrowing capacity option $ 275,000,000.0                    
Commitment fee percentage 0.25%                    
Bridge Loan | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Credit line capacity $ 20,000,000.0                    
Letter of Credit | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Credit line capacity $ 20,000,000.0                    
LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Estimated credit spread 2.50%                    
LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Estimated credit spread 0.35%                    
LIBOR, thereafter | Revolving Credit Facility | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Estimated credit spread 0.50%                    
LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Estimated credit spread 1.35%                    
LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                      
Debt Instrument [Line Items]                      
Estimated credit spread 1.50%